Merck & Co is on the brink of plugging a gap in the coronavirus treatment armamentarium after its oral drug molnupiravir cut deaths and hospitalisations in mild or moderate COVID-19 in a phase 3 ...
German Consumer Sentiment Sinks on Income Expectations; EUR/USD Holds LossesWed, 26 Feb 2025 11:03:15 GMT Dow Jones: Nvidia’s Strong Results Power Tech Stocks as Tariff Worries PersistThu, 27 ...
At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated ...
Laboratory studies show that Merck & Co's experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, including the dominant ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
Nath figured the drug might have a similar effect in people with long COVID, based in part on the PML results. Last June, Nath approached Merck to ask for supplies of Keytruda to test that hypothesis.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE ... were arthralgia, COVID-19, nasopharyngitis, and fatigue. One participant on DOR/ISL discontinued due to a drug-related serious AE (immune ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback